ANI Pharmaceuticals (NASDAQ:ANIP) Earns Buy Rating from Guggenheim

Guggenheim reiterated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research report released on Tuesday, Benzinga reports. The firm currently has a $77.00 target price on the specialty pharmaceutical company’s stock.

A number of other analysts have also recently weighed in on ANIP. Capital One Financial started coverage on shares of ANI Pharmaceuticals in a report on Friday, March 15th. They set an overweight rating and a $80.00 target price on the stock. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a buy rating in a report on Friday, March 1st. Finally, HC Wainwright increased their price objective on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a buy rating in a report on Monday, March 4th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of Buy and an average target price of $80.00.

ANI Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ:ANIP opened at $64.95 on Tuesday. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of 76.89 and a beta of 0.79. ANI Pharmaceuticals has a 1-year low of $36.99 and a 1-year high of $70.81. The company’s fifty day moving average is $65.53 and its two-hundred day moving average is $58.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.81 and a current ratio of 3.57.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $131.65 million for the quarter, compared to analysts’ expectations of $123.02 million. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. Equities analysts anticipate that ANI Pharmaceuticals will post 3.55 EPS for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $67.25, for a total transaction of $1,345,000.00. Following the completion of the transaction, the senior vice president now owns 253,226 shares in the company, valued at approximately $17,029,448.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, COO Muthusamy Shanmugam sold 16,809 shares of the firm’s stock in a transaction dated Friday, April 19th. The shares were sold at an average price of $65.17, for a total transaction of $1,095,442.53. Following the completion of the transaction, the chief operating officer now owns 782,620 shares in the company, valued at approximately $51,003,345.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $67.25, for a total transaction of $1,345,000.00. Following the completion of the transaction, the senior vice president now owns 253,226 shares of the company’s stock, valued at $17,029,448.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 156,803 shares of company stock valued at $10,363,466. Company insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of ANI Pharmaceuticals by 5.4% in the third quarter. Vanguard Group Inc. now owns 1,132,378 shares of the specialty pharmaceutical company’s stock worth $65,746,000 after buying an additional 58,204 shares during the period. Rubric Capital Management LP lifted its position in shares of ANI Pharmaceuticals by 32.8% in the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock worth $62,032,000 after purchasing an additional 277,989 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of ANI Pharmaceuticals by 6.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock worth $32,628,000 after purchasing an additional 33,359 shares in the last quarter. Global Alpha Capital Management Ltd. lifted its position in shares of ANI Pharmaceuticals by 10.8% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock worth $32,115,000 after purchasing an additional 56,900 shares in the last quarter. Finally, Ranger Investment Management L.P. lifted its position in shares of ANI Pharmaceuticals by 1.8% in the fourth quarter. Ranger Investment Management L.P. now owns 434,617 shares of the specialty pharmaceutical company’s stock worth $23,965,000 after purchasing an additional 7,769 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.